Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06544291 · ClinicalTrials.gov registry record · Phase 2
Combined THC and CBD for OUD and Chronic Pain
A Phase 2 study of Chronic Pain and Opioid Use Disorder, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 147
- Enrollment target
- 1
- Study location
NCT06544291: Recruiting Phase 2 study of Chronic Pain and Opioid Use Disorder, sponsored by Yale University.
NCT06544291 is a Phase 2 study of Chronic Pain and Opioid Use Disorder that is actively recruiting participants, run by Yale University. The registered enrollment target is 147 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06544291, a Phase 2 study of Chronic Pain and Opioid Use Disorder, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 147 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this phase 2 study is to investigate the therapeutic potential of orally administered combined delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in relieving both pain and cue-induced opioid craving in people with co-occurring opioid use disorder (OUD) and chronic pain who are undergoing methadone therapy.
Primary Outcome
We will measure pain sensitivity using a comprehensive QST battery at baseline and approximately hourly for 8 hours. The battery includes several nociceptive modalities such as pressure, mechanical, heat, and cold stimuli. The main outcome will be a composite pain sensitivity measure, integrating data from the QST battery.
Conditions Studied
Interventions
- DRUG CBD 300mg
- DRUG CBD 600mg
- DRUG Placebo 0mg
Study Locations (1)
Connecticut
- Connecticut Mental Health Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2024-10-22 |
| Est. Completion | 2028-01-28 |
| Phase | Phase 2 |
What NCT06544291 shows while recruiting
NCT06544291 is an interventional study that assigns participants to a tested intervention. The registered 147 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (81% lower).
The record links to 2 conditions, with Chronic Pain appearing as the primary indexed condition, and to 3 interventions - of which CBD 300mg is the first listed.
NCT06544291 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT06544291 about?
NCT06544291 is a clinical study titled "Combined THC and CBD for OUD and Chronic Pain". The primary objective of this phase 2 study is to investigate the therapeutic potential of orally administered combined delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in relieving both pain and cue-induced opioid craving in people with co-occurring opioid use disorder (OUD) and chronic pai...
What is the current status of trial NCT06544291?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 147 participants. The study started on 2024-10-22. Estimated completion is 2028-01-28.
What conditions does trial NCT06544291 study?
This clinical trial studies the following conditions: Chronic Pain, Opioid Use Disorder.
What interventions are being tested in trial NCT06544291?
The interventions under investigation include: CBD 300mg (DRUG), CBD 600mg (DRUG), Placebo 0mg (DRUG).
Who is sponsoring clinical trial NCT06544291?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06544291 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06544291's enrollment target sits among peer trials
147 107th of 301 higher than 195 of 301 other Chronic Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PAIN: a Project Assessing the Impact of a Novel Cannabinoid Product
RECRUITING · Phase 2
-
The Role of Brain Dopamine in Chronic Pain
RECRUITING · Phase 2
-
Generate and Test the Reliability of a PD Model of OXT on Pupillary Hippus as a Measure of CNS Activity
RECRUITING · Phase 2
-
A Mobile Intervention to Reduce Pain and Improve Health-III
RECRUITING · Phase 2
-
Dronabinol as an Adjunct for Reducing Pain
RECRUITING · Phase 2
-
Pilot Study: Impact of Biomarker-Guided Dietary Supplementation on Quality-of-Life Measures in Subjects With Chronic Pain
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04396613 · 147 participants · NA
Wound Closure Techniques in Primary Spine Surgery
- NCT04851119 · 147 participants · Phase 1
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NCT05523947 · 147 participants · Phase 1
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
- NCT06121843 · 147 participants · Phase 1
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI